

SHORT TITLE: Maverick-HCM

RESEARCH PROTOCOL TITLE: A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacamten (MYK-461) in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

PRINCIPAL INVESTIGATOR: Matt Wolff, MD

RESEARCH SPONSOR: MyoKardia, Inc.

Clinical Trials.Gov Listing at:

<https://clinicaltrials.gov/ct2/show/NCT03442764?term=mavacamten&cond=Hypertrophic+Cardiomyopathy&rank=3>

STUDY PURPOSE

This study evaluates the safety and tolerability of a 16-week course of mavacamten (the investigational medication) in patients with symptomatic Hypertrophic Cardiomyopathy (a condition where the heart becomes thickened without an obvious cause).

STUDY PROCEDURES

Participation in the study can last up to 28 weeks with 8 in clinic visits and three phone call visits. During clinic visits blood will be drawn, an ultrasound of the heart may be done, a treadmill test may be done, questionnaires may be done and a physical exam will be done.

ELIGIBILITY CRITERIA FOR SUBJECTS

1. 18 years of age or older
2. Be able to walk on a treadmill
3. Give informed consent and comply with study procedures

SUBJECT PAYMENT

Compensation will range from \$25-\$75 per visit.

RESEARCH LOCATION AND CONTACT PERSON

Lynn Skatrud, RN, CCRC
UnityPoint Health-Meriter-Heart & Vascular Institute
2601 West Beltline Hwy.
Suite 200
Madison, WI 53713

PHONE: 608-417-2168